MV NIS

Drug Profile

MV NIS

Alternative Names: MVNIS; Sodium Iodide Simporter Measles Virus

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vyriad
  • Class Antineoplastics; Cancer vaccines; Oncolytic viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Medulloblastoma; Non-small cell lung cancer; Rhabdoid tumour
  • Preclinical Haematological malignancies

Most Recent Events

  • 03 Aug 2017 Phase-I clinical trials in Non-small cell lung cancer (Recurrent, Metastatic disease, Combination therapy) in USA (Intratumoural) (NCT02919449)
  • 05 Jun 2017 Vyriad plans a phase I trial for Urothelial cancer (Neoadjuvant therapy, First-line therapy) (NCT03171493)
  • 02 Nov 2016 The University of California in collaboration with Vyriad plans a phase I trial in Medulloblastoma (Locally recurrent, Second-line therapy or greater, In infants, In children, In adolescents, In adults) (NCT02962167)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top